eXoZymes (EXOZ) investor relations material

Investment thesis

• NCT is positioned as the first potent activator of HNF4α, a target described as resistant to 30 years of drug discovery; two randomized, placebo-controlled trials met primary endpoints.

• The presentation frames obesity, diabetes and fatty liver disease as interconnected disorders, citing 1.2B, 800M+ and 2.5B affected people, respectively; NAFLD is projected to double by 2040.

• The nutraceutical opportunity is presented as a $100B+ accessible market; cited global dietary supplement market was $209.5B in 2025.

Target and preclinical findings

• HNF4α regulates thousands of genes linked to liver, pancreas and gut function; human genetic studies associate reduced activity with MODY1 diabetes, MASLD/MASH and IBD.

• NCT is described as a naturally occurring, selective HNF4α agonist that may support mitochondrial performance, liver fat clearance and gut barrier integrity; claims are not FDA-evaluated.

• In animal models, NCT produced 30–40% less weight gain on the same high-fat diet and equal calories, alongside improved mitochondrial measures, liver steatosis and gut barrier markers.

Human evidence and safety

• A 126-person prediabetes trial met its primary endpoint at 4 weeks; fasting glucose fell further than placebo, with fasting insulin and post-meal glucose also improving.

• A 29-person IBS-D trial met its primary endpoint at 3 weeks; gut permeability fell significantly versus placebo, symptom scores improved and no adverse events were reported.

• An estimated safe dose of 992 mg/day, derived from published 90-day toxicology, is planned for submission for GRAS; the trials used 120 mg/day of an encapsulated synthetic NCT/NFT blend.